Ry Pharma


Despite their discovery 100 to 150 years ago, the pathogenesis of neuromuscular and neurologic diseases is unknown.

Other than symptom treatment, currently no treatment is available for many devastating neuromuscular and neurologic diseases, including ALS, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease.

Ry Pharma develops treatments for the symptoms of these neuromuscular and neurologic diseases.


Ry Pharma was founded by Dr. Bert Tuk, an expert on the inhibitory system and its role in neurological and neuromuscular diseases.

Scientific publications of Dr. Tuk on the inhibitory (GABA) system are:

Treatment with penicillin G and hydrocortisone reduces ALS-associated symptoms: a case series of three patients. Tuk B, Jousma H and Gaillard PJ. F1000Research 2017, 6:410,

Syphilis may be a confounding factor, not a causative agent, in syphilitic ALS. Tuk B. F1000Res. 2016 Aug 2;5:1904.

Overstimulation of the inhibitory nervous system plays a role in the pathogenesis of neuromuscular and neurological diseases: a novel hypothesis. Tuk B. F1000Res. 2016 Jun 20.

Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. Tuk B, van Gool T, Danhof M. J Pharmacokinet Pharmacodyn. 2002 Jun;29(3):235-50.

Analysis of a sleep-dependent neuronal feedback loop: the slow-wave microcontinuity of the EEG.Kemp B, Zwinderman AH, Tuk B, Kamphuisen HA, Oberyé JJ. IEEE Trans Biomed Eng. 2000

A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Karlsson MO, Schoemaker RC, Kemp B, Cohen AF, van Gerven JM, Tuk B, Peck CC, Danhof M. Clin Pharmacol Ther. 2000 Aug;68(2):175-88.

Model-based delta plots beat power-based ones. Kemp B, Zwinderman AH, Tuk B, Kamphuisen HA, Oberyé JJ. Electroencephalogr Clin Neurophysiol Suppl. 1999;50:341-8. No abstract available.

Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. J Pharmacol Exp Ther. 1999 May;289(2):1067-74.

Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. Tuk B, Herben VM, Mandema JW, Danhof M. J Pharmacol Exp Ther. 1998 Jan;284(1):202-7.

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Tuk B, Oberyé JJ, Pieters MS, Schoemaker RC, Kemp B, van Gerven J, Danhof M, Kamphuisen HA, Cohen AF, Breimer DD, Peck CC. Clin Pharmacol Ther. 1997 Oct;62(4):444-52.

The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. Tuk B, Danhof M, Mandema JW. J Pharmacokinet Biopharm. 1997 Feb;25(1):39-62.

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol.van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, Breimer DD, Cohen AF. Br J Clin Pharmacol. 1996 Jun;41(6):565-73.

A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Van Steveninck AL, Mandema JW, Tuk B, Van Dijk JG, Schoemaker HC, Danhof M, Cohen AF. Br J Clin Pharmacol. 1993 Aug;36(2):109-15.

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Clin Pharmacol Ther. 1992 Jun;51(6):715-28.